Evidence map›Paper›PMID 37467168›Full record

ArticleJournal of medicinal chemistry2023

Determination of Ligand-Binding Affinity (

Manjuan Liu, Amin Mirza, P Craig McAndrew, Arjun Thapaliya, Olivier A Pierrat, Mark Stubbs, Tamas Hahner, Nicola E A Chessum, Paolo Innocenti, John Caldwell and 7 more

Abstract read
In one paragraph

Article in Journal of medicinal chemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Review
  3. EstablishingAnalytical chemistry · 2026
    Article
  4. Article
  5. Article
  6. Target Engagement Assays in Early Drug Discovery.Journal of medicinal chemistry · 2025
    Review
  7. Direct Quantification of Protein-Protein Interactions in Living Bacterial Cells.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Manjuan LiuCentre for Cancer Drug Discovery, The Institute of Cancer Research, London SM2 5NG, U.K.ORCID 0000-0002-8411-0148
Amin MirzaCentre for Cancer Drug Discovery, The Institute of Cancer Research, London SM2 5NG, U.K.
P Craig McAndrewCentre for Cancer Drug Discovery, The Institute of Cancer Research, London SM2 5NG, U.K.ORCID 0000-0002-1366-088X
Arjun ThapaliyaCentre for Cancer Drug Discovery, The Institute of Cancer Research, London SM2 5NG, U.K.
Olivier A PierratCentre for Cancer Drug Discovery, The Institute of Cancer Research, London SM2 5NG, U.K.
Mark StubbsCentre for Cancer Drug Discovery, The Institute of Cancer Research, London SM2 5NG, U.K.
Tamas HahnerCentre for Cancer Drug Discovery, The Institute of Cancer Research, London SM2 5NG, U.K.
Nicola E A ChessumCentre for Cancer Drug Discovery, The Institute of Cancer Research, London SM2 5NG, U.K.ORCID 0000-0003-4125-320X
Paolo InnocentiCentre for Cancer Drug Discovery, The Institute of Cancer Research, London SM2 5NG, U.K.
John CaldwellCentre for Cancer Drug Discovery, The Institute of Cancer Research, London SM2 5NG, U.K.
Matthew D CheesemanCentre for Cancer Drug Discovery, The Institute of Cancer Research, London SM2 5NG, U.K.ORCID 0000-0003-1121-6985
Benjamin R BellenieCentre for Cancer Drug Discovery, The Institute of Cancer Research, London SM2 5NG, U.K.ORCID 0000-0001-9987-3079
Rob L M van MontfortCentre for Cancer Drug Discovery, The Institute of Cancer Research, London SM2 5NG, U.K.
Gary K NewtonCentre for Cancer Drug Discovery, The Institute of Cancer Research, London SM2 5NG, U.K.
Rosemary BurkeCentre for Cancer Drug Discovery, The Institute of Cancer Research, London SM2 5NG, U.K.
Ian CollinsCentre for Cancer Drug Discovery, The Institute of Cancer Research, London SM2 5NG, U.K.
Swen HoelderCentre for Cancer Drug Discovery, The Institute of Cancer Research, London SM2 5NG, U.K.

Funding

Cancer Research UK C309/A11566
6 · The paper itself

Abstract

High hit rates from initial ligand-observed NMR screening can make it challenging to prioritize which hits to follow up, especially in cases where there are no available crystal structures of these hits bound to the target proteins or other strategies to provide affinity ranking. Here, we report a reproducible, accurate, and versatile quantitative ligand-observed NMR assay, which can determine

Indexed as

Drug DiscoverySmall Molecule LibrariesLigandsProtein BindingProton Magnetic Resonance SpectroscopyReproducibility of ResultsLigandsSmall Molecule Libraries

Identifiers

PMID37467168
PMCPMC10424183

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.